Metastasis accounts for almost 90% of cancer-associated mortality. The effectiveness of cancer therapeutics is limited by the protective microenvironment of the metastatic niche and consequently these disseminated tumors remain incurable. Metastatic disease progression continues to be poorly understood due to the lack of appropriate model systems. To address this gap in understanding, we propose an all-human microphysiological system that facilitates the investigation of cancer behavior in the liver metastatic niche. This existing LiverChip is a 3D-system modeling the hepatic niche; it incorporates a full complement of human parenchymal and non-parenchymal cells and effectively recapitulates micrometastases. Moreover, this system allows real-time monitoring of micrometastasis and assessment of human-specific signaling. It is being utilized to further our understanding of the efficacy of chemotherapeutics by examining the activity of established and novel agents on micrometastases under conditions replicating diurnal variations in hormones, nutrients and mild inflammatory states using programmable microdispensers. These inputs affect the cues that govern tumor cell responses. Three critical signaling groups are targeted: the glucose/insulin responses, the stress hormone cortisol and the gut microbiome in relation to inflammatory cues. Currently, the system sustains functioning hepatocytes for a minimum of 15 days; confirmed by monitoring hepatic function (urea, α-1-antitrypsin, fibrinogen, and cytochrome P450) and injury (AST and ALT). Breast cancer cell lines effectively integrate into the hepatic niche without detectable disruption to tissue, and preliminary evidence suggests growth attenuation amongst a subpopulation of breast cancer cells. xMAP technology combined with systems biology modeling are also employed to evaluate cellular crosstalk and illustrate communication networks in the early microenvironment of micrometastases. This model is anticipated to identify new therapeutic strategies for metastasis by elucidating the paracrine effects between the hepatic and metastatic cells, while concurrently evaluating agent efficacy for metastasis, metabolism and tolerability.
ChristiansenJJRajasekaranAK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res2006; 66: 8319–26.
2.
TaylorDPWellsJZSavolAChennubhotlaCWellsA. Modeling boundary conditions for balanced proliferation in metastatic latency. Clin Cancer Res2013; 19: 1063–70.
3.
WeinbergRA. The many faces of tumor dormancy. APMIS2008; 116: 548–51.
4.
O'ShaughnessyJ. Extending survival with chemotherapy in metastatic breast cancer. Oncologist2005; 10(Suppl 3): 20–9.
5.
HackamDGRedelmeierDA. Translation of research evidence from animals to humans. JAMA2006; 296: 1731–2.
6.
MestasJHughesCC. Of mice and not men: differences between mouse and human immunology. J Immunol2004; 172: 2731–8.
7.
FantozziAChristoforiG. Mouse models of breast cancer metastasis. Breast Cancer Res2006; 8: 212–212.
8.
KhannaCHunterK. Modeling metastasis in vivo. Carcinogenesis2005; 26: 513–23.
9.
TeicherBA. Tumor models for efficacy determination. Mol Cancer Ther2006; 5: 2435–43.
10.
JunttilaMRde SauvageFJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature2013; 501: 346–54.
11.
SlaneyCYRautelaJParkerBS. The emerging role of immunosurveillance in dictating metastatic spread in breast cancer. Cancer Res2013; 73: 5852–7.
NelsonCMVanduijnMMInmanJLFletcherDABissellMJ. Tissue geometry determines sites of mammary branching morphogenesis in organotypic cultures. Science2006; 314: 298–300.
15.
RidkyTWChowJMWongDJKhavariPA. Invasive three-dimensional organotypic neoplasia from multiple normal human epithelia. Nat Med2010; 16: 1450–5.
16.
ShawKRWrobelCNBruggeJS. Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis. J Mammary Gland Biol Neoplasia2004; 9: 297–310.
17.
StroockADFischbachC. Microfluidic culture models of tumor angiogenesis. Tissue Eng Part A2010; 16: 2143–6.
18.
Grever MR, Grieshaber CK. Toxicology by Organ System. In: Bast RC Jr, Kufe DW, Pollock RE, et al. (eds) Holland-Frei Cancer Medicine. 5th edition. Hamilton (ON): BC Decker; 2000. Chapter 45. Available at: http://www.ncbi.nlm.nih.gov/books/NBK20792/.
19.
Pickren J, Tsukada Y, Lane W. Liver metastasis: analysis of autopsy data. In: Weiss L, Gilbert L (eds) Liver metastasis. Boston, MA: G.K. Hall Medical Publishers, 1982, pp.2–18.
20.
GuengerichFPTurvyCG. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther1991; 256: 1189–94.
21.
CrispeIN. The liver as a lymphoid organ. Annu Rev Immunol2009; 27: 147–63.
22.
ShimadaTYamazakiHMimuraMInuiYGuengerichFP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther1994; 270: 414–23.
23.
SlaughterRLEdwardsDJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother1995; 29: 619–24.
24.
WilkinsonGR. Drug metabolism and variability among patients in drug response. N Engl J Med2005; 352: 2211–21.
25.
FuLLeeCC. The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer2003; 3: 350–61.
26.
LeviFSchiblerU. Circadian rhythms: mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol2007; 47: 593–28.
27.
GodoyPHewittNJAlbrechtUAndersenMEAnsariNBhattacharyaSBodeJGBolleynJBornerCBottgerJBraeuningABudinskyRABurkhardtBCameronNRCamussiGChoCSChoiYJCraig RowlandsJDahmenUDammGDirschODonatoMTDongJDooleySDrasdoDEakinsRFerreiraKSFonsatoVFraczekJGebhardtRGibsonAGlanemannMGoldringCEGomez-LechonMJGroothuisGMGustavssonLGuyotCHallifaxDHammadSHaywardAHaussingerDHellerbrandCHewittPHoehmeSHolzhutterHGHoustonJBHrachJItoKJaeschkeHKeitelVKelmJMKevin ParkBKordesCKullak-UblickGALeCluyseELLuPLuebke-WheelerJLutzAMaltmanDJMatz-SojaMMcMullenPMerfortIMessnerSMeyerCMwinyiJNaisbittDJNusslerAKOlingaPPampaloniFPiJPlutaLPrzyborskiSARamachandranARogiersVRoweCSchelcherCSchmichKSchwarzMSinghBStelzerEHStiegerBStoberRSugiyamaYTettaCThaslerWEVanhaeckeTVinkenMWeissTSWideraAWoodsCGXuJJYarboroughKMHengstlerJG. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol2013; 87: 1315–30.
DunnJCTompkinsRGYarmushML. Long-term in vitro function of adult hepatocytes in a collagen sandwich configuration. Biotechnol Prog1991; 7: 237–45.
30.
KhetaniSRBhatiaSN. Microscale culture of human liver cells for drug development. Nat Biotechnol2008; 26: 120–6.
31.
BissellDMArensonDMMaherJJRollFJ. Support of cultured hepatocytes by a laminin-rich gel. Evidence for a functionally significant subendothelial matrix in normal rat liver. J Clin Invest1987; 79: 801–12.
32.
ClaytonDFHarrelsonALDarnellJEJr. Dependence of liver-specific transcription on tissue organization. Mol Cell Biol1985; 5: 2623–32.
33.
GodoyPHengstlerJGIlkavetsIMeyerCBachmannAMullerATuschlGMuellerSODooleyS. Extracellular matrix modulates sensitivity of hepatocytes to fibroblastoid dedifferentiation and transforming growth factor beta-induced apoptosis. Hepatology2009; 49: 2031–43.
34.
KoideNShinjiTTanabeTAsanoKKawaguchiMSakaguchiKKoideYMoriMTsujiT. Continued high albumin production by multicellular spheroids of adult rat hepatocytes formed in the presence of liver-derived proteoglycans. Biochem Biophys Res Commun1989; 161: 385–91.
35.
TongJZDe LagausiePFurlanVCresteilTBernardOAlvarezF. Long-term culture of adult rat hepatocyte spheroids. Exp Cell Res1992; 200: 326–32.
36.
TakeshitaKBowenWCMichalopoulosGK. Three-dimensional culture of hepatocytes in a continuously flowing medium. In Vitro Cell Dev Biol Anim1998; 34: 482–85.
37.
AllenJWKhetaniSRBhatiaSN. In vitro zonation and toxicity in a hepatocyte bioreactor. Toxicol Sci2005; 84: 110–19.
38.
NovikEMaguireTJChaoPChengKCYarmushML. A microfluidic hepatic coculture platform for cell-based drug metabolism studies. Biochem Pharmacol2010; 79: 1036–44.
39.
ChaoYWuQAcquafondataMDhirRWellsA. Partial mesenchymal to epithelial reverting transition in breast and prostate cancer metastases. Cancer Microenviron2012; 5: 19–28.
40.
ChaoYLShepardCRWellsA. Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer2010; 9: 179–179.
41.
YatesCShepardCRPapworthGDashABeer StolzDTannenbaumSGriffithLWellsA. Novel three-dimensional organotypic liver bioreactor to directly visualize early events in metastatic progression. Adv Cancer Res2007; 97: 225–46.
42.
YatesCCShepardCRStolzDBWellsA. Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin. Br J Cancer2007; 96: 1246–52.
43.
ChaoYWuQShepardCWellsA. Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance. Clin Exp Metastasis2012; 29: 39–50.
44.
Wheeler S, Borenstein J, Clark AM, Ebrahimkhani M, Fox IJ, Griffith L, Inman W, Lauffenburger DA, Nguyen T, Pillai VC, Prantil-Baun R, Stolz DB, Taylor DP, Ulrich T, Venkataramanan R, Wells A, Young C. All-human microphysical model of metastasis therapy. Stem Cell Res Ther 2013;4(Supp 1):S11.
45.
HewesJCRiddyDMorrisRWWoodrooffeAJDavidsonBRFullerB. A prospective study of isolated human hepatocyte function following liver resection for colorectal liver metastases: the effects of prior exposure to chemotherapy. J Hepatol2006; 45: 263–70.
46.
HengstlerJGBrulportMSchormannWBauerAHermesMNusslerAKFandrichFRuhnkeMUngefrorenHGriffinLBockampEOeschFvon MachMA. Generation of human hepatocytes by stem cell technology: definition of the hepatocyte. Expert Opin Drug Metab Toxicol2005; 1: 61–74.
47.
KnobelochDEhnertSSchyschkaLBuchlerPSchoenbergMKleeffJThaslerWENusslerNCGodoyPHengstlerJNusslerAK. Human hepatocytes: isolation, culture, and quality procedures. Methods Mol Biol2012; 806: 99–120.
48.
PillaiVCStromSCCaritisSNVenkataramananR. A sensitive and specific CYP cocktail assay for the simultaneous assessment of human cytochrome P450 activities in primary cultures of human hepatocytes using LC-MS/MS. J Pharm Biomed Anal2013; 74: 126–32.
49.
WellsRG. The role of matrix stiffness in regulating cell behavior. Hepatology2008; 47: 1394–1400.
50.
ChafferCLBrennanJPSlavinJLBlickTThompsonEWWilliamsED. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res2006; 66: 11271–8.
51.
KowalskiPJRubinMAKleerCG. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res2003; 5: R217–222.
52.
TarinDThompsonEWNewgreenDF. The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res2005; 65: 5996–6000. discussion 6000-5991.
53.
WellsAYatesCShepardCR. E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis2008; 25: 621–8.
54.
HorningJLSahooSKVijayaraghavaluSDimitrijevicSVasirJKJainTKPandaAKLabhasetwarV. 3-D tumor model for in vitro evaluation of anticancer drugs. Mol Pharm2008; 5: 849–62.
55.
MitraMMohantyCHarilalAMaheswariUKSahooSKKrishnakumarS. A novel in vitro three-dimensional retinoblastoma model for evaluating chemotherapeutic drugs. Mol Vis2012; 18: 1361–78.
56.
SungJHShulerML. A micro cell culture analog (microCCA) with 3-D hydrogel culture of multiple cell lines to assess metabolism-dependent cytotoxicity of anti-cancer drugs. Lab Chip2009; 9: 1385–94.
57.
LeeGYKennyPALeeEHBissellMJ. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods2007; 4: 359–65.
58.
LeviFFocanCKaraboueAde la ValetteVFocan-HenrardDBaronBKreutzFGiacchettiS. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev2007; 59: 1015–35.
59.
LeeCRaffaghelloLBrandhorstSSafdieFMBianchiGMartin-MontalvoAPistoiaVWeiMHwangSMerlinoAEmioniteLde CaboRLongoVD. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med2012; 4: 124–7.
60.
OhdoS. Circadian rhythms in the CNS and peripheral clock disorders: chronopharmacological findings on antitumor drugs. J Pharmacol Sci2007; 103: 155–8.
61.
BernabeDGTamaeACBiasoliEROliveiraSH. Stress hormones increase cell proliferation and regulates interleukin-6 secretion in human oral squamous cell carcinomas. Brain Behv Immun2011; 25: 574–83.
62.
Aguirre-GhisoJA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer2007; 7: 834–46.
63.
BarkanDEl TounyLHMichalowskiAMSmithJAChuIDavisASWebsterJDHooverSSimpsonRMGauldieJGreenJE. Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Res2010; 70: 5706–16.
64.
WendtMKTaylorMASchiemannBJSchiemannWP. Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer. Mol Biol Cell2011; 22: 2423–35.
65.
MatsusueRKuboHHisamoriSOkoshiKTakagiHHidaKNakanoKItamiAKawadaKNagayamaSSakaiY. Hepatic stellate cells promote liver metastasis of colon cancer cells by the action of SDF-1/CXCR4 axis. Ann Surg Oncol2009; 16: 2645–53.
66.
PaschosKAMajeedAWBirdNC. Role of Kupffer cells in the outgrowth of colorectal cancer liver metastases. Hepatol Res2010; 40: 83–94.
67.
GaoDNolanDJMellickASBambinoKMcDonnellKMittalV. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science2008; 319: 195–8.
68.
HochstBSchildbergFABottcherJMetzgerCHussSTurlerAOverhausMKnoblichASchneiderBPantelisDKurtsCKalffJCKnollePDiehlL. Liver sinusoidal endothelial cells contribute to CD8 T cell tolerance toward circulating carcinoembryonic antigen in mice. Hepatology2012; 56: 1924–33.
69.
SceneayJSmythMJMollerA. The pre-metastatic niche: finding common ground. Cancer Metastasis Rev2013; 32: 449–64.
IdekerTWinslowLRLauffenburgerAD. Bioengineering and systems biology. Ann Biomed Eng2006; 34: 257–64.
72.
JoughinBANaegleKMHuangPHYaffeMBLauffenburgerDAWhiteFM. An integrated comparative phosphoproteomic and bioinformatic approach reveals a novel class of MPM-2 motifs upregulated in EGFRvIII-expressing glioblastoma cells. Mol Biosyst2009; 5: 59–67.
73.
DashAInmanWHoffmasterKSevidalSKellyJObachRSGriffithLGTannenbaumSR. Liver tissue engineering in the evaluation of drug safety. Expert Opin Drug Metab Toxicol2009; 5: 1159–74.
74.
SiolasDHannonGJ. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res2013; 73: 5315–19.
75.
HirschhaeuserFSattlerUGMueller-KlieserW. Lactate: a metabolic key player in cancer. Cancer Res2011; 71: 692125–692125.
76.
MillerMABarkalLJengKHerrlichAMossMGriffithLGLauffenburgerDA. Proteolytic Activity Matrix Analysis (PrAMA) for simultaneous determination of multiple protease activities. Integr Biol (Camb)2011; 3: 422–38.
